| Dengue vaccine group Control group
|
|
Age cohort |
2–5 yrs |
6–11 yrs |
12–17 |
yrs |
18–45 yrs |
All |
|
2–5 yrs |
6–11 yrs |
12–17 |
yrs |
18–45 yrs |
All |
|
N |
40 |
40 |
20 |
|
20 |
120 |
|
20 |
20 |
10 |
|
10 |
60 |
|
Male/n (%) |
19 (48) |
23(58) |
7 (35) |
|
9 (45) |
58(48) |
|
13 (65) |
13 (65) |
4 (40) |
|
5 (50) |
35 (58) |
|
Mean age/years |
4.2 |
8.4 |
13.3 |
|
27.0 |
|
|
4.6 |
9.0 |
13.4 |
|
29.9 |
|
|
BMI/kg/m2 |
15.3 |
16.3 |
17.9 |
|
22.7 |
|
|
14.5 |
16.5 |
17.8 |
|
21.4 |
|
|
Baseline seropositivity/n (%) |
|
JE |
2 (5) |
2 (5) |
1 (5) |
1(5) |
6 (5) |
|
2 (10) |
4 (20) |
2 (20) |
0 (0) |
8 (13) |
|
|
|
Dengue |
23 (58) |
28(70) |
14 (70) |
19(95) |
85 (71) |
|
12(60) |
11 (55) |
8 (80) |
9 (90) |
40 (67) |
|
|
|
Dengue or JE |
26 (65) |
30(75) |
15 (75) |
20(100) |
91 (76) |
|
14(70) |
15 (75) |
10 (100) |
9 (90) |
48 (80) |
|
|
|
